Gypenosides Alleviate Hyperglycemia by Regulating Gut Microbiota Metabolites and Intestinal Permeability

Area of Science:

• Metabolic diseases
• Gut microbiome
• Gut-liver axis

Background:

• Gypenosides (Gps), active compounds from Gynostemma, show anti-diabetic potential.
• The precise molecular mechanisms underlying Gps' anti-diabetic effects remain incompletely understood.
• Clarifying these mechanisms is crucial for developing effective diabetes management strategies.

Purpose of the Study:

• To elucidate the molecular mechanisms by which Gypenosides (Gps) ameliorate glucose dysregulation.
• To investigate the impact of Gps on metabolic homeostasis, gut microbiota, and the gut-liver axis.
• To provide novel insights into the therapeutic potential of Gps for type 2 diabetes mellitus.

Main Methods:

• Establishment of type 2 diabetes mellitus mouse models treated with varying doses of Gps.
• Analysis of biochemical markers, hepatic and colonic histopathology, and gut microbiota composition.
• Metabolomic analysis of short-chain fatty acids (SCFAs) and bile acids (BAs); Western blotting for signaling pathway activation.

Main Results:

• Gps treatment improved glucose/lipid profiles, reduced inflammatory markers, and alleviated hepatic damage.
• Gps enhanced gut barrier integrity by upregulating tight junction proteins (ZO-1, occludin).
• Gps modulated gut microbiota, increasing diversity and beneficial bacteria, while promoting SCFA production and reshaping BA profiles.
• Gps activated the hepatic PI3K/AKT pathway and the intestinal BA/FXR/FGF15 axis.

Conclusions:

• Gypenosides effectively ameliorate hyperglycemia and hyperlipidemia through multifaceted mechanisms.
• Key mechanisms include gut microbiota modulation, intestinal barrier restoration, and regulation of SCFAs and BAs.
• Findings highlight the role of the gut-liver axis in Gps' anti-diabetic action.